Weight Regain After Stopping Semaglutide: The Evidence
Trial data (STEP-1 extension, STEP-4) show most people regain a substantial share of lost weight within a year of stopping semaglutide. This reframes GLP-1s as long-term therapies rather than short courses. STEP-1 extension data showed participants regained a substantial share of lost weight within a year of stopping, which is why clinicians frame GLP-1 medications as long-term therapy rather than a short course.
- STEP extension data showed substantial weight regain after stopping semaglutide.
- In STEP-1 follow-up, participants regained about two-thirds of lost weight within a year.
- STEP-4 showed continued treatment maintained loss while withdrawal led to regain.
- This is why GLP-1s are framed as long-term, not short-course, therapies.
What the evidence shows
The clearest data come from the STEP trials. In the STEP-1 extension, participants who stopped semaglutide regained a large share of their lost weight — roughly two-thirds — within about a year. STEP-4 was designed specifically to test this: participants who continued semaglutide maintained their loss, while those switched to placebo regained weight.
The pattern is consistent and physiological: the drug amplifies satiety signaling, and removing it returns appetite toward baseline.
Why regain happens
Obesity is increasingly understood as a chronic condition with a defended body-weight set point. GLP-1 drugs lower that set point while taken, but do not permanently reset it. When the drug stops, the biological drivers of appetite and weight regulation reassert themselves, and weight tends to return.
This is not a failure of willpower or of the drug; it is the expected consequence of removing an active treatment for a chronic condition, much as blood pressure rises again when antihypertensives are stopped.
| Study | Finding |
|---|---|
| STEP-1 extension | ~2/3 of lost weight regained within ~1 year of stopping |
| STEP-4 | Continued treatment maintained loss; withdrawal led to regain |
| Applies to compounded? | No formulation-specific data |
What it means for treatment
The regain evidence reframes how GLP-1s should be understood: as long-term therapies for a chronic condition, not short courses for temporary loss. This has practical implications for cost, since long-term treatment means ongoing expense, and for decision-making, since starting implies a potentially indefinite commitment.
It also means that stopping should be a deliberate, clinician-guided decision, ideally with a plan for maintaining weight through other means, rather than an abrupt halt.
| Implication | Detail |
|---|---|
| Long-term therapy | Regain expected after stopping |
| Cost | Ongoing expense to maintain loss |
| Stopping | Should be clinician-guided |
The compounded caveat
This evidence comes from trials of FDA-approved semaglutide. Compounded formulations have no formulation-specific data on regain or maintenance, so while the underlying molecule is the same, the specific trial findings apply to the approved products studied.
The broader lesson — that these are long-term therapies and stopping tends to bring regain — is a reasonable expectation for anyone considering a GLP-1, regardless of formulation, and worth discussing with a prescriber before starting.
Frequently asked questions
Will I regain weight if I stop semaglutide?
Trial data show most people regain a substantial share — roughly two-thirds in STEP-1 follow-up — within about a year of stopping. GLP-1s are long-term therapies.
Why do you regain weight?
Obesity is a chronic condition with a defended set point. The drug lowers it while taken but does not permanently reset it, so weight returns when treatment stops.
Should I plan to take it forever?
Starting implies a potentially long-term commitment. Stopping should be a deliberate, clinician-guided decision with a maintenance plan.
Sources
- Clinical trials via NEJM.
- STEP-1 extension and STEP-4 trial data.
- FDA — human drug compounding and GLP-1 status.